Scarica l'app Stockscreener
0.4139
6.36%
-0.0281
Dopo l'orario di chiusura:
.42
0.0061
+1.47%
Moleculin Biotech Inc Borsa (MBRX) Ultime notizie
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit - Yahoo! Finance Canada
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit - GlobeNewswire
Signal Proxy Intelligence Recommends AGAINST Moleculin Biotech, Inc. Executive Compensation Ahead of Oct. 9, 2026 Annual Meeting (NASDAQ:MBRX) - www.hastingsstargazette.com
Form 8-K Moleculin Biotech, Inc. For: Oct 05 - StreetInsider
Moleculin Biotech stock reaches 89-patient MIRACLE milestone2d4f8a6b-9c3e-4f1a-b7d2-5e8c0a6f3b91 - AD HOC NEWS
Price to earnings forward of Moleculin Biotech, Inc. – NASDAQ:MBRX - TradingView
Certain Pre-Funded Warrants of Moleculin Biotech, Inc. are subject to a Lock-Up Agreement Ending on 3-OCT-2026. - marketscreener.com
Moleculin Biotech CS (MBRX-Q) Stock Price and News - The Globe and Mail
Moleculin completes enrollment in Annamycin AML trial Part A - Investing.com
Form 8K Moleculin Biotech Inc For: 29 September By Investing.com - Investing.com UK
Moleculin completes enrollment in Annamycin AML trial Part A By Investing.com - Investing.com Canada
Moleculin Biotech completes Part A enrollment in MIRACLE; 89 patients, Q1 2027 readout on track - TradingView
Moleculin Biotech Completes Enrollment in Part A of Phase - GlobeNewswire
A leukemia trial finished enrolling 89 people. Full results are expected in early 2027. - Stock Titan
Moleculin Biotech Reports Peer-Reviewed Cardiac Safety Analysis of Annamycin - Kalkine Media
Moleculin reports cardiac safety data for Annamycin in study - Investing.com
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine - GlobeNewswire Inc.
A review found no signs of heart damage in 90 patients given a cancer drug - Stock Titan
Moleculin Announces Publication of Peer-Reviewed Cardiac - globenewswire.com
Form 8K Moleculin Biotech Inc For: 25 September By Investing.com - Investing.com Nigeria
Moleculin presents preclinical pancreatic cancer data at AACR - Investing.com
Form 8K Moleculin Biotech Inc For: 25 September By Investing.com - Investing.com UK
A cancer drug may help immune cells attack pancreatic tumors, early tests suggest. - Stock Titan
Moleculin Biotech, Inc. (MBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Moleculin Biotech (NASDAQ: MBRX) Obtains Mexican Patent No. 436849 and Issues 888,400 Shares via ATM Offering - Kalkine Media
Moleculin Biotech Announces Mexican Patent Approval and ATM Share Offering Completion - Kalkine Media
Moleculin Biotech (MBRX) Strengthens IP with Mexican Patent Amid Challenging Valuation - GuruFocus
Form 8K Moleculin Biotech Inc For: 23 September By Investing.com - Investing.com Canada
Moleculin receives Mexican patent for Annamycin formulation - Investing.com
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 - globenewswire.com
A drug formulation designed to reach lung tumors has Mexican patent protection through 2040. - Stock Titan
Moleculin Biotech stock falls 32.71 percent on September 21 - AD HOC NEWS
Form 8K Moleculin Biotech Inc For: 18 September By Investing.com - Investing.com Nigeria
Moleculin Biotech Stock Price Forecast. Should You Buy MBRX? - StockInvest.us
Moleculin Biotech receives Nasdaq delisting notice after minimum bid price violation - Investing.com
Moleculin Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Moleculin Biotech risks Nasdaq delisting after shares stay below $1 bid threshold - Bitget
Moleculin to Showcase New Annamycin Data at AACR Conference - GlobeNewswire
Moleculin Biotech at H.C. Wainwright conference: aml hope builds By Investing.com - Investing.com Australia
Moleculin Biotech at H.C. Wainwright conference: aml hope builds - Investing.com
Moleculin Biotech at H.C. Wainwright conference: aml hope builds By Investing.com - Investing.com Canada
MBRX: Annamycin's Phase III AML trial shows triple the remission rate of control with zero cardiotoxicity - TradingView
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand - The Manila Times
A biotech’s clinical update goes online before New York investor meetings - stocktitan.net
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand - Yahoo Finance
Moleculin Biotech (MBRX) Holds Above $0.77 as Biotech Sector Watches Key Resistance at $0.81Trend Following Picks - siam.in
Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team - ACCESS Newswire
Moleculin Biotech Updates Investors with New Presentation - TipRanks
Moleculin (NASDAQ: MBRX) posts investor presentation online - stocktitan.net
MOLECULIN BIOTECH, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $3 FROM $22 - webull.com
1.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):